Chronic insomnia is common in adults with intellectual disabilities, yet evidence to guide pharmacological management is limited. We report a real-world case series of five adults with intellectual disabilities and multimorbidity treated with daridorexant, a dual orexin receptor antagonist approved in Europe for insomnia. Daridorexant was associated with marked improvements in sleep quality and quantity, despite complex comorbid sleep, physical, mental and neurodevelopmental disorders. Subject…
